{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:27:14Z","timestamp":1787318834760,"version":"build-2736575974"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03220-9","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:50:27Z","timestamp":1747630227000},"page":"3111-3140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances in Clinical Cardiology 2024: A Summary of Key Clinical Trials"],"prefix":"10.1007","volume":"42","author":[{"given":"Patrick","family":"Savage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meadhbh","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"McElhatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Menown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"36","key":"3220_CR1","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European society of cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3415\u2013537.","journal-title":"Eur Heart J"},{"issue":"6","key":"3220_CR2","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.athoracsur.2021.01.078","volume":"111","author":"MJ Mack","year":"2021","unstructured":"Mack MJ, Fullerton DA, Fann JI. The answers you get depend on the questions you ask: insights from the recent EXCEL trial controversy. Ann Thorac Surg. 2021;111(6):1743\u20135.","journal-title":"Ann Thorac Surg"},{"issue":"10318","key":"3220_CR3","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/S0140-6736(21)02334-5","volume":"398","author":"MS Sabatine","year":"2021","unstructured":"Sabatine MS, Bergmark BA, Murphy SA, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021;398(10318):2247\u201357.","journal-title":"Lancet"},{"issue":"18","key":"3220_CR4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2407791","volume":"391","author":"V Kunadian","year":"2024","unstructured":"Kunadian V, Mossop H, Shields C, et al. Invasive treatment strategy for older patients with myocardial infarction. N Engl J Med. 2024;391(18):1673\u201384.","journal-title":"N Engl J Med"},{"issue":"19","key":"3220_CR5","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1161\/CIRCULATIONAHA.124.071493","volume":"150","author":"G Campo","year":"2024","unstructured":"Campo G, B\u00f6hm F, Engstr\u00f8m T, et al. Complete versus culprit-only revascularization in older patients with ST-segment-elevation myocardial infarction: an individual patient meta-analysis. Circulation. 2024;150(19):1508\u201316.","journal-title":"Circulation"},{"issue":"7","key":"3220_CR6","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1007\/s12325-024-02877-y","volume":"41","author":"P Savage","year":"2024","unstructured":"Savage P, Cox B, Shahmohammadi M, Kelly B, Menown I. Advances in clinical cardiology 2023: a summary of key clinical trials. Adv Ther. 2024;41(7):2606\u201334.","journal-title":"Adv Ther"},{"issue":"15","key":"3220_CR7","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","volume":"390","author":"JE M\u00f8ller","year":"2024","unstructured":"M\u00f8ller JE, Engstr\u00f8m T, Jensen LO, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390(15):1382\u201393.","journal-title":"N Engl J Med"},{"key":"3220_CR8","unstructured":"Clinicaltrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05506449. Accessed 2025 Feb 19."},{"issue":"15","key":"3220_CR9","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","volume":"390","author":"T Yndigegn","year":"2024","unstructured":"Yndigegn T, Lindahl B, Mars K, et al. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med. 2024;390(15):1372\u201381.","journal-title":"N Engl J Med"},{"issue":"14","key":"3220_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa2404204","volume":"391","author":"J Silvain","year":"2024","unstructured":"Silvain J, Cayla G, Ferrari E, et al. Beta-blocker interruption or continuation after myocardial infarction. N Engl J Med. 2024;391(14):1277\u201386.","journal-title":"N Engl J Med"},{"issue":"6","key":"3220_CR11","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s12325-022-02136-y","volume":"39","author":"P Savage","year":"2022","unstructured":"Savage P, Cox B, Linden K, Coburn J, Shahmohammadi M, Menown I. Advances in clinical cardiology 2021: a summary of key clinical trials. Adv Ther. 2022;39(6):2398\u2013437.","journal-title":"Adv Ther"},{"issue":"10439","key":"3220_CR12","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","volume":"403","author":"Z Ge","year":"2024","unstructured":"Ge Z, Kan J, Gao X, et al. Ticagrelor alone versus ticagrelor plus aspirin from month\u00a01 to month\u00a012 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024;403(10439):1866\u201378.","journal-title":"Lancet"},{"issue":"10456","key":"3220_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","volume":"404","author":"M Valgimigli","year":"2024","unstructured":"Valgimigli M, Hong SJ, Gragnano F, et al. De-escalation to ticagrelor monotherapy versus 12\u00a0months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024;404(10456):937\u201348.","journal-title":"Lancet"},{"issue":"6","key":"3220_CR14","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1007\/s12325-020-01355-5","volume":"37","author":"K Linden","year":"2020","unstructured":"Linden K, Mailey J, Kearney A, Menown IBA. Advances in clinical cardiology 2019: a summary of key clinical trials. Adv Ther. 2020;37(6):2620\u201345.","journal-title":"Adv Ther"},{"key":"3220_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405922","author":"SS Jolly","year":"2024","unstructured":"Jolly SS, d\u2019Entremont MA, Lee SF, et al. Colchicine in acute myocardial infarction. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2405922.","journal-title":"N Engl J Med"},{"issue":"10457","key":"3220_CR16","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S0140-6736(24)01594-0","volume":"404","author":"C Gao","year":"2024","unstructured":"Gao C, He X, Ouyang F, et al. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial. Lancet. 2024;404(10457):1040\u201350.","journal-title":"Lancet"},{"issue":"18_Supplement","key":"3220_CR17","doi-asserted-by":"publisher","first-page":"B88","DOI":"10.1016\/j.jacc.2024.09.400","volume":"84","author":"S Fezzi","year":"2024","unstructured":"Fezzi S, Giacoppo D, Fahrni G, et al. TCT-346 assessment of long-term clinical outcomes of De Novo DCB performance: a comprehensive, individual patient data meta-analysis of randomized clinical trials: final results of the ANDROMEDA study. J Am Coll Cardiol. 2024;84(18_Supplement):B88\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"3220_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jama.2024.1361","volume":"331","author":"RW Yeh","year":"2024","unstructured":"Yeh RW, Shlofmitz R, Moses J, et al. Paclitaxel-coated balloon vs uncoated balloon for coronary in-stent restenosis: the AGENT IDE randomized clinical trial. JAMA. 2024;331(12):1015\u201324.","journal-title":"JAMA"},{"issue":"24","key":"3220_CR19","first-page":"08451","volume":"S0735\u20131097","author":"X Gao","year":"2024","unstructured":"Gao X, Tian N, Kan J, et al. Drug-coated balloon angioplasty of the side branch during provisional stenting: the multicenter randomized DCB-BIF trial. J Am Coll Cardiol. 2024;S0735\u20131097(24):08451\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3220_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052788","volume":"12","author":"XF Gao","year":"2022","unstructured":"Gao XF, Ge Z, Kan J, et al. Rationale and design for comparison of non-compliant balloon with drug-coating balloon angioplasty for side branch after provisional stenting for patients with true coronary bifurcation lesions: a prospective, multicentre and randomised DCB-BIF trial. BMJ Open. 2022;12(3):e052788.","journal-title":"BMJ Open"},{"key":"3220_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102304","volume":"65","author":"S Saito","year":"2023","unstructured":"Saito S, Bennett J, Nef HM, et al. First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with de novo coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT. EClinicalMedicine. 2023;65:102304.","journal-title":"EClinicalMedicine"},{"issue":"10464","key":"3220_CR22","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(24)02227-X","volume":"404","author":"D Erlinge","year":"2024","unstructured":"Erlinge D, Andersson J, Fr\u00f6bert O, et al. Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial. Lancet. 2024;404(10464):1750\u20139.","journal-title":"Lancet"},{"key":"3220_CR23","doi-asserted-by":"publisher","first-page":"e082945","DOI":"10.1136\/bmj-2024-082945","volume":"388","author":"C Gao","year":"2025","unstructured":"Gao C, Zhu B, Ouyang F, Wen S, Xu Y, Jia W, Yang P, He Y, Zhong Y, Zhou Y, Guo Z, Shen G, Ma L, Xu L, Xue Y, Hu T, Wang Q, Liu Y, Zhang R, Liu J, Jiang Z, Xia J, Garg S, van Geuns RJ, Capodanno D, Onuma Y, Wang D, Serruys P, Tao L. REC-CAGEFREE II Investigators. Stepwise dual antiplatelet therapy de-escalation in patients after drug coated balloon angioplasty (REC-CAGEFREE II): multicentre, randomised, open label, assessor blind, non-inferiority trial. BMJ. 2025;388:e082945. https:\/\/doi.org\/10.1136\/bmj-2024-082945.","journal-title":"BMJ."},{"issue":"41","key":"3220_CR24","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1093\/eurheartj\/ehad582","volume":"44","author":"A Eftekhari","year":"2023","unstructured":"Eftekhari A, Holck EN, Westra J, et al. Instantaneous wave free ratio vs. fractional flow reserve and 5-year mortality: iFR SWEDEHEART and DEFINE FLAIR. Eur Heart J. 2023;44(41):4376\u201384.","journal-title":"Eur Heart J"},{"issue":"3","key":"3220_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028423","volume":"12","author":"K Berntorp","year":"2023","unstructured":"Berntorp K, Rylance R, Yndigegn T, et al. Clinical outcome of revascularization deferral with instantaneous wave-free ratio and fractional flow reserve: a 5-year follow-up substudy from the iFR-SWEDEHEART trial. J Am Heart Assoc. 2023;12(3):e028423.","journal-title":"J Am Heart Assoc"},{"issue":"10438","key":"3220_CR26","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(24)00413-6","volume":"403","author":"SJ Park","year":"2024","unstructured":"Park SJ, Ahn JM, Kang DY, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024;403(10438):1753\u201365.","journal-title":"Lancet"},{"issue":"10465","key":"3220_CR27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(24)02175-5","volume":"404","author":"BK Andersen","year":"2024","unstructured":"Andersen BK, Sejr-Hansen M, Maillard L, et al. Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR\u00a0III Europe): a multicentre, randomised, non-inferiority trial. Lancet. 2024;404(10465):1835\u201346.","journal-title":"Lancet"},{"issue":"23 Pt A","key":"3220_CR28","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.jacc.2018.09.006","volume":"72","author":"TJ Ford","year":"2018","unstructured":"Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol. 2018;72(23 Pt A):2841\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3220_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4244\/EIJ-D-24-00499","volume":"21","author":"A Jer\u00f3nimo","year":"2025","unstructured":"Jer\u00f3nimo A, Paredes-V\u00e1zquez JG, Travieso A, et al. Comprehensive diagnosis in chronic coronary syndromes combining angiography and intracoronary testing: the AID-ANGIO study. EuroIntervention Cardiol. 2025;21(1):35\u201345.","journal-title":"EuroIntervention"},{"key":"3220_CR30","unstructured":"Van Rosendael A. AI-guided quantitative coronary CT angiography (AI-QCT) technology in patients with suspected coronary artery disease: findings from a global multi-center registry. Presented at: TCT 2024. Washington, DC; 2024."},{"issue":"18_Supplement","key":"3220_CR31","doi-asserted-by":"publisher","first-page":"B169","DOI":"10.1016\/j.jacc.2024.09.588","volume":"84","author":"N Amabile","year":"2024","unstructured":"Amabile N, Motreff P, Landolff Q, et al. TCT-509 predictors of stent under expansion in the CALIPSO trial. J Am Coll Cardiol. 2024;84(18_Supplement):B169\u2013B169.","journal-title":"J Am Coll Cardiol"},{"issue":"10457","key":"3220_CR32","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S0140-6736(24)01454-5","volume":"404","author":"SJ Hong","year":"2024","unstructured":"Hong SJ, Lee SJ, Lee SH, et al. Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea. Lancet. 2024;404(10457):1029\u201339.","journal-title":"Lancet"},{"key":"3220_CR33","unstructured":"Kirtane AJ. ECLIPSE: a large-scale, randomized trial of orbital atherectomy vs. conventional balloon angioplasty in severely calcified coronary arteries prior to DES implantation. Presented at: TCT 2024. Washington, DC; 2024."},{"issue":"10436","key":"3220_CR34","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(24)00256-3","volume":"403","author":"MJ Foley","year":"2024","unstructured":"Foley MJ, Rajkumar CA, Ahmed-Jushuf F, et al. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial. Lancet. 2024;403(10436):1543\u201353.","journal-title":"Lancet"},{"issue":"9","key":"3220_CR35","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcin.2018.01.271","volume":"11","author":"M Tajstra","year":"2018","unstructured":"Tajstra M, Hrapkowicz T, Hawranek M, et al. Hybrid coronary revascularization in selected patients with multivessel disease: 5-year clinical outcomes of the prospective randomized pilot study. JACC Cardiovasc Interv. 2018;11(9):847\u201352.","journal-title":"JACC Cardiovasc Interv"},{"key":"3220_CR36","unstructured":"Tajstra M. Hybrid coronary revascularization. 10-year clinical outcomes of the prospective randomized study. Presented at: EuroPCR 2024. Paris, France; 2024"},{"issue":"6","key":"3220_CR37","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s12325-023-02502-4","volume":"40","author":"P Savage","year":"2023","unstructured":"Savage P, Cox B, Shahmohammadi M, Foster J, Menown I. Advances in clinical cardiology 2022: a summary of key clinical trials. Adv Ther. 2023;40(6):2595\u2013625.","journal-title":"Adv Ther"},{"issue":"17","key":"3220_CR38","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2400685","volume":"390","author":"S Blankenberg","year":"2024","unstructured":"Blankenberg S, Seiffert M, Vonthein R, et al. Transcatheter or surgical treatment of aortic-valve stenosis. N Engl J Med. 2024;390(17):1572\u201383.","journal-title":"N Engl J Med"},{"issue":"37","key":"3220_CR39","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1093\/eurheartj\/ehae331","volume":"45","author":"TH J\u00f8rgensen","year":"2024","unstructured":"J\u00f8rgensen TH, Thyregod HGH, Savontaus M, et al. Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial. Eur Heart J. 2024;45(37):3804\u201314.","journal-title":"Eur Heart J"},{"issue":"7","key":"3220_CR40","volume":"3","author":"G Talanas","year":"2024","unstructured":"Talanas G, Laconi A, Kereiakes DJ, et al. Long-term outcomes of transcatheter vs surgical aortic valve replacement: meta-analysis of randomized trials. J Soc Cardiovasc Angiogr Interv. 2024;3(7):102143.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"3220_CR41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405880","author":"P G\u00e9n\u00e9reux","year":"2024","unstructured":"G\u00e9n\u00e9reux P, Schwartz A, Oldemeyer JB, et al. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2405880.","journal-title":"N Engl J Med"},{"key":"3220_CR42","volume":"28","author":"K Loganath","year":"2024","unstructured":"Loganath K, Craig NJ, Everett RJ, et al. Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the EVOLVED randomized clinical trial. JAMA. 2024;28:e2422730.","journal-title":"JAMA"},{"issue":"24","key":"3220_CR43","first-page":"09960","volume":"S0735\u20131097","author":"NM Van Mieghem","year":"2024","unstructured":"Van Mieghem NM, Elmariah S, Spitzer E, et al. Transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis: TAVR UNLOAD. J Am Coll Cardiol. 2024;S0735\u20131097(24):09960\u20131.","journal-title":"J Am Coll Cardiol"},{"key":"3220_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.4278","author":"RR Makkar","year":"2024","unstructured":"Makkar RR, Gupta A, Waggoner TE, et al. Cerebral embolic protection by geographic region: a post hoc analysis of the PROTECTED TAVR randomized clinical trial. JAMA Cardiol. 2024. https:\/\/doi.org\/10.1001\/jamacardio.2024.4278.","journal-title":"JAMA Cardiol"},{"key":"3220_CR45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401513","author":"J L\u00f8nborg","year":"2024","unstructured":"L\u00f8nborg J, Jabbari R, Sabbah M, et al. PCI in patients undergoing transcatheter aortic-valve implantation. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2401513.","journal-title":"N Engl J Med"},{"issue":"1","key":"3220_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4244\/EIJ-D-19-00056","volume":"15","author":"I Komatsu","year":"2019","unstructured":"Komatsu I, Mackensen GB, Aldea GS, Reisman M, Dvir D. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction. Part 2: how to perform BASILICA. EuroIntervention. 2019;15(1):55\u201366.","journal-title":"EuroIntervention"},{"issue":"33","key":"3220_CR47","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1093\/eurheartj\/ehae303","volume":"45","author":"D Dvir","year":"2024","unstructured":"Dvir D, Tch\u00e9tch\u00e9 D, Leon MB, et al. Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study. Eur Heart J. 2024;45(33):3031\u201341.","journal-title":"Eur Heart J"},{"key":"3220_CR48","doi-asserted-by":"publisher","first-page":"102603","DOI":"10.1016\/j.eclinm.2024.102603","volume":"72","author":"S Chang","year":"2024","unstructured":"Chang S, Jiang Z, Liu X, et al. Permanent pacemaker reduction using temporary-permanent pacemaker as a 1-month bridge after transcatheter aortic valve replacement: a prospective, multicentre, single-arm, observational study. eClinicalMedicine. 2024;72:102603.","journal-title":"eClinicalMedicine"},{"issue":"12","key":"3220_CR49","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/jamacardio.2024.3241","volume":"9","author":"D Tch\u00e9tch\u00e9","year":"2024","unstructured":"Tch\u00e9tch\u00e9 D, Mehran R, Blackman DJ, et al. Transcatheter aortic valve implantation by valve type in women with small annuli: results from the SMART randomized clinical trial. JAMA Cardiol. 2024;9(12):1106\u201314.","journal-title":"JAMA Cardiol"},{"issue":"24","key":"3220_CR50","first-page":"09954","volume":"S0735\u20131097","author":"SV Arnold","year":"2024","unstructured":"Arnold SV, Hahn RT, Thourani VH, et al. Quality of life after transcatheter tricuspid valve replacement: 1-year results from TRISCEND\u00a0II pivotal trial. J Am Coll Cardiol. 2024;S0735\u20131097(24):09954\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"3220_CR51","doi-asserted-by":"publisher","unstructured":"Baldus S, Doenst T, Pfister R, et al. Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation. N Engl J Med. 2024;391(19):1787\u20131798. https:\/\/doi.org\/10.1056\/NEJMoa2408739.","DOI":"10.1056\/NEJMoa2408739"},{"issue":"19","key":"3220_CR52","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa2314328","volume":"391","author":"SD Anker","year":"2024","unstructured":"Anker SD, Friede T, von Bardeleben RS, et al. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med. 2024;391(19):1799\u2013809.","journal-title":"N Engl J Med"},{"issue":"2","key":"3220_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa2401918","volume":"392","author":"RT Hahn","year":"2025","unstructured":"Hahn RT, Makkar R, Thourani VH, et al. Transcatheter valve replacement in severe tricuspid regurgitation. N Engl J Med. 2025;392(2):115\u201326.","journal-title":"N Engl J Med"},{"issue":"3","key":"3220_CR54","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jacc.2024.10.086","volume":"85","author":"GHL Tang","year":"2025","unstructured":"Tang GHL, Hahn RT, Whisenant BK, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. J Am Coll Cardiol. 2025;85(3):235\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"3220_CR55","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jama.2024.17921","volume":"332","author":"R Dulai","year":"2024","unstructured":"Dulai R, Sulke N, Freemantle N, et al. Pulmonary vein isolation vs sham intervention in symptomatic atrial fibrillation: the SHAM-PVI randomized clinical trial. JAMA. 2024;332(14):1165\u201373.","journal-title":"JAMA"},{"issue":"7 Pt 2","key":"3220_CR56","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.jacep.2024.05.005","volume":"10","author":"EP Gerstenfeld","year":"2024","unstructured":"Gerstenfeld EP, Mansour M, Whang W, et al. Autonomic effects of pulsed field vs thermal ablation for treating atrial fibrillation: subanalysis of ADVENT. JACC Clin Electrophysiol. 2024;10(7 Pt 2):1634\u201344.","journal-title":"JACC Clin Electrophysiol"},{"issue":"8","key":"3220_CR57","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.hrthm.2024.04.102","volume":"21","author":"MK Turagam","year":"2024","unstructured":"Turagam MK, Neuzil P, Petru J, et al. AF ablation using a novel \u201csingle-shot\u201d map-and-ablate spherical array pulsed field ablation catheter: 1-year outcomes of the first-in-human PULSE-EU trial. Heart Rhythm. 2024;21(8):1218\u201326.","journal-title":"Heart Rhythm"},{"issue":"8","key":"3220_CR58","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/s41591-024-03022-6","volume":"30","author":"E Anter","year":"2024","unstructured":"Anter E, Mansour M, Nair DG, et al. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med. 2024;30(8):2303\u201310.","journal-title":"Nat Med"},{"issue":"7","key":"3220_CR59","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41591-024-03114-3","volume":"30","author":"E Ekanem","year":"2024","unstructured":"Ekanem E, Neuzil P, Reichlin T, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med. 2024;30(7):2020\u20139.","journal-title":"Nat Med"},{"key":"3220_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03517-w","author":"I Deisenhofer","year":"2025","unstructured":"Deisenhofer I, Albenque JP, Busch S, et al. Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03517-w.","journal-title":"Nat Med"},{"issue":"9","key":"3220_CR61","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.hrthm.2024.05.022","volume":"21","author":"V Boyalla","year":"2024","unstructured":"Boyalla V, Haldar S, Khan H, et al. Long-term clinical outcomes and cost-effectiveness of catheter vs thoracoscopic surgical ablation in long-standing persistent atrial fibrillation using continuous cardiac monitoring: CASA-AF randomized controlled trial. Heart Rhythm. 2024;21(9):1562\u20139.","journal-title":"Heart Rhythm"},{"key":"3220_CR62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407362","author":"MS Cho","year":"2024","unstructured":"Cho MS, Kang DY, Ahn JM, et al. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2407362.","journal-title":"N Engl J Med"},{"issue":"12","key":"3220_CR63","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","volume":"381","author":"S Yasuda","year":"2019","unstructured":"Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103\u201313.","journal-title":"N Engl J Med"},{"issue":"5","key":"3220_CR64","first-page":"e35","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021;143(5):e35-71.","journal-title":"Circulation"},{"key":"3220_CR65","doi-asserted-by":"crossref","unstructured":"Izumi C. Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical bioprosthetic vALVe replacement. Presented at: AHA 2024. Chicago, IL; 2024.","DOI":"10.21203\/rs.3.rs-3828221\/v1"},{"key":"3220_CR66","unstructured":"K\u00fchne M. Impact of atrial fibrillation on brain infarcts and cognitive function: a matched cohort analysis. Presented at: EHRA 2024. Berlin, Germany; 2024."},{"key":"3220_CR67","unstructured":"Rivard L. The BRAIN-AF Trial. Presented at AHA. November 16, 2024. Chicago, IL."},{"key":"3220_CR68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408308","author":"OM Wazni","year":"2024","unstructured":"Wazni OM, Saliba WI, Nair DG, et al. Left atrial appendage closure after ablation for atrial fibrillation. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2408308.","journal-title":"N Engl J Med"},{"key":"3220_CR69","unstructured":"Kotecha D. STEEER-AF\u2014stroke prevention & rhythm control therapy: evaluation of an education programme of the European society of cardiology in a cluster-randomised trial in patients with atrial fibrillation. Presented at: ESC 2024. London, England; 2024."},{"key":"3220_CR70","unstructured":"Chung MK. Randomized controlled trial of metformin and lifestyle\/risk factor modification for upstream prevention of atrial fibrillation progression the targeting risk interventions and metformin for atrial fibrillation (TRIM-AF) trial. Presented at: AHA 2024. Chicago, IL; 2024"},{"key":"3220_CR71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409501","author":"JL Sapp","year":"2024","unstructured":"Sapp JL, Tang ASL, Parkash R, et al. Catheter ablation or antiarrhythmic drugs for ventricular tachycardia. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2409501.","journal-title":"N Engl J Med"},{"issue":"4","key":"3220_CR72","doi-asserted-by":"publisher","first-page":"euae076","DOI":"10.1093\/europace\/euae076","volume":"26","author":"A Verma","year":"2024","unstructured":"Verma A, Essebag V, Neuzil P, et al. Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies. Europace. 2024;26(4):euae076.","journal-title":"Europace"},{"key":"3220_CR73","doi-asserted-by":"publisher","first-page":"6829725","DOI":"10.1155\/2022\/6829725","volume":"2022","author":"JA Lurz","year":"2022","unstructured":"Lurz JA, Schmidt E, Kresoja KP, et al. Relevance of chronic total occlusion for outcome of ventricular tachycardia ablation in ischemic cardiomyopathy. J Intervent Cardiol. 2022;2022:6829725.","journal-title":"J Intervent Cardiol"},{"issue":"5","key":"3220_CR74","doi-asserted-by":"publisher","first-page":"euae109","DOI":"10.1093\/europace\/euae109","volume":"26","author":"D \u017di\u017eek","year":"2024","unstructured":"\u017di\u017eek D, Mrak M, Jan M, et al. Impact of preventive substrate catheter ablation on implantable cardioverter-defibrillator interventions in patients with ischaemic cardiomyopathy and infarct-related coronary chronic total occlusion. Europace. 2024;26(5):euae109.","journal-title":"Europace"},{"issue":"25","key":"3220_CR75","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1056\/NEJMoa2300080","volume":"388","author":"RE Knops","year":"2023","unstructured":"Knops RE, Reddy VY, Ip JE, et al. A dual-chamber leadless pacemaker. N Engl J Med. 2023;388(25):2360\u201370.","journal-title":"N Engl J Med"},{"key":"3220_CR76","unstructured":"Aveir DR. Dual-chamber leadless pacemaker looks solid at 1\u00a0year | tctmd.com. https:\/\/www.tctmd.com\/news\/aveir-dr-dual-chamber-leadless-pacemaker-looks-solid-1-year. Accessed 2024 Dec 13."},{"issue":"10","key":"3220_CR77","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.hrthm.2024.04.067","volume":"21","author":"GH Crossley","year":"2024","unstructured":"Crossley GH, Sanders P, Hansky B, et al. Safety, efficacy, and reliability evaluation ofa novel small-diameter defibrillation lead: Global LEADR pivotal trial results. Heart Rhythm. 2024;21(10):1914\u201322.","journal-title":"Heart Rhythm"},{"issue":"15","key":"3220_CR78","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type\u00a02 diabetes. N Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"key":"3220_CR79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","author":"M Packer","year":"2024","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"issue":"16","key":"3220_CR80","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385.","journal-title":"N Engl J Med"},{"issue":"16","key":"3220_CR81","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390(16):1455\u201366.","journal-title":"N Engl J Med"},{"key":"3220_CR82","doi-asserted-by":"crossref","unstructured":"Bene-Alhasan Y. Electronic nicotine product use is associated with incident heart failure: the All of Us research program. Presented at: ACC 2024. Atlanta, GA; 2024","DOI":"10.1016\/S0735-1097(24)02685-8"},{"issue":"37","key":"3220_CR83","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503\u2013626.","journal-title":"Eur Heart J"},{"issue":"42","key":"3220_CR84","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1093\/eurheartj\/ehae590","volume":"45","author":"CJ Coats","year":"2024","unstructured":"Coats CJ, Masri A, Barriales-Villa R, et al. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. Eur Heart J. 2024;45(42):4464\u201378.","journal-title":"Eur Heart J"},{"issue":"21","key":"3220_CR85","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","volume":"83","author":"MS Maron","year":"2024","unstructured":"Maron MS, Mahmod M, Abd Samat AH, et al. Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2024;83(21):2037\u201348.","journal-title":"J Am Coll Cardiol"},{"key":"3220_CR86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134","author":"M Fontana","year":"2024","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","journal-title":"N Engl J Med"},{"issue":"24","key":"3220_CR87","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.124.070870","volume":"150","author":"GW Stone","year":"2024","unstructured":"Stone GW, Lindenfeld J, Rod\u00e9s-Cabau J, et al. Interatrial shunt treatment for heart failure: the randomized RELIEVE-HF trial. Circulation. 2024;150(24):1931\u201343.","journal-title":"Circulation"},{"key":"3220_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3563","author":"N Girerd","year":"2025","unstructured":"Girerd N, Barbet V, Seronde MF, et al. Association of a remote monitoring programme with all-cause mortality and hospitalizations in patients with heart failure: National-scale, real-world evidence from a 3-year propensity score analysis of the TELESAT-HF study. Eur J Heart Fail. 2025. https:\/\/doi.org\/10.1002\/ejhf.3563.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"3220_CR89","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/ejhf.3267","volume":"26","author":"J Malgie","year":"2024","unstructured":"Malgie J, Wilde MI, Clephas PRD, et al. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: first data from the TITRATE-HF study. Eur J Heart Fail. 2024;26(7):1549\u201360.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"3220_CR90","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jchf.2024.03.001","volume":"12","author":"SJ Greene","year":"2024","unstructured":"Greene SJ, Ayodele I, Pierce JB, et al. Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure. JACC Heart Fail. 2024;12(8):1365\u201377.","journal-title":"JACC Heart Fail"},{"issue":"24","key":"3220_CR91","first-page":"00623","volume":"S2213\u20131779","author":"A Spahillari","year":"2024","unstructured":"Spahillari A, Cohen LP, Lin C, et al. Efficacy, safety and mechanistic impact of a heart failure guideline-directed medical therapy clinic. JACC Heart Fail. 2024;S2213\u20131779(24):00623\u201331.","journal-title":"JACC Heart Fail"},{"issue":"20","key":"3220_CR92","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, et al. An \u201cinclisiran first\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83(20):1939\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"3220_CR93","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","volume":"45","author":"J Schubert","year":"2024","unstructured":"Schubert J, Leosdottir M, Lindahl B, et al. Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry. Eur Heart J. 2024;45(39):4204\u201315.","journal-title":"Eur Heart J"},{"issue":"9","key":"3220_CR94","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","volume":"9","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol. 2024;9(9):800\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2024.1659.","journal-title":"JAMA Cardiol"},{"issue":"19","key":"3220_CR95","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024;390(19):1770\u201380.","journal-title":"N Engl J Med"},{"issue":"10","key":"3220_CR96","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, et al. Plozasiran, an RNA Interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):899\u2013912.","journal-title":"N Engl J Med"},{"key":"3220_CR97","volume":"18","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Ni W, Rhodes GM, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA. 2024;18:e2424017.","journal-title":"JAMA"},{"key":"3220_CR98","volume":"18","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, et al. Zerlasiran-A small-interfering RNA targeting lipoprotein(a): a phase\u00a02 randomized clinical trial. JAMA. 2024;18: e2421957.","journal-title":"JAMA"},{"key":"3220_CR99","unstructured":"Eli Lilly and Company. A phase\u00a03, randomized, double-blind, placebo-controlled study to investigate the effect of lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) who have established atherosclerotic cardiovascular disease or are at risk for a first cardiovascular event-ACCLAIM-Lp(a). clinicaltrials.gov; 2025. Report No. NCT06292013. https:\/\/clinicaltrials.gov\/study\/NCT06292013. Accessed 2025 Mar 24."},{"key":"3220_CR100","unstructured":"Amgen. A double-blind, randomized, placebo-controlled, multicenter study assessing the impact of olpasiran on major cardiovascular events in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a). clinicaltrials.gov; 2024. Report No.: NCT05581303. https:\/\/clinicaltrials.gov\/study\/NCT05581303. Accessed 2025 Mar 24."},{"key":"3220_CR101","unstructured":"Novartis Pharmaceuticals. A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease. clinicaltrials.gov; 2025. Report No. NCT04023552. https:\/\/clinicaltrials.gov\/study\/NCT04023552. Accessed 2025 Mar 24."},{"issue":"21","key":"3220_CR102","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1016\/j.jacc.2024.03.388","volume":"83","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Hutchinson HG, Wolski K, et al. A technology-assisted web application for consumer access to a nonprescription statin medication. J Am Coll Cardiol. 2024;83(21):2080\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"3220_CR103","unstructured":"Upton R. A prospective randomised controlled trial evaluating the use of artificial intelligence in stress echocardiography. Presented at: ESC 2024. London, England; 2024."},{"key":"3220_CR104","unstructured":"Desai AS. Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension: primary results from the phase\u00a02 KARDIA-2 study. Presented at: ACC 2024. Atlanta, GA; 2024"},{"issue":"10449","key":"3220_CR105","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120\u00a0mm Hg versus less than 140\u00a0mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245\u201355.","journal-title":"Lancet"},{"issue":"2","key":"3220_CR106","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059711","volume":"12","author":"SR Garrison","year":"2022","unstructured":"Garrison SR, Kolber MR, Allan GM, et al. Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial. BMJ Open. 2022;12(2):e059711.","journal-title":"BMJ Open"},{"issue":"10462","key":"3220_CR107","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/S0140-6736(24)01744-6","volume":"404","author":"A Rodgers","year":"2024","unstructured":"Rodgers A, Salam A, Schutte AE, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024;404(10462):1536\u201346.","journal-title":"Lancet"},{"key":"3220_CR108","unstructured":"Taddei S. QUADRO phase\u00a0III study: efficacy and safety of the first quadruple SPC perindopril\/indapamide\/amlodipine\/bisoprolol in patients with resistant hypertension. Presented at: ESC 2024. August 31. London, England; 2024"},{"issue":"24","key":"3220_CR109","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.124.069291","volume":"149","author":"DE Kandzari","year":"2024","unstructured":"Kandzari DE, Weber MA, Pathak A, et al. Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive medications: primary results from the TARGET BP I randomized clinical trial. Circulation. 2024;149(24):1875\u201384.","journal-title":"Circulation"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03220-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03220-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03220-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T05:02:35Z","timestamp":1750482155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03220-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":109,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3220"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03220-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ian Menown has received grants to institution, honoraria and\/or conference sponsorship from Biosensors and Novartis. Ian Menown is an editorial board member of\n                      Advances in Therapy\n                      . Ian Menown was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Patrick Savage, Michael Campbell, Daniel McElhatton and Meadhbh Hogg have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}